gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

U2AF homology motif

Kis
The gene encodes a serine/threonine protein kinase that promotes cell cycle progression through G1 by phosphorylation of the cyclin-dependent kinase inhibitor 1B (p27Kip1), which causes nuclear export and degradation. The encoded protein is also thought to function in the adult nervous system and the gene has been associated with schizophrenia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2010] (from NCBI)
Top mentioned proteins: ACID, HAD, CAN, V1a, Cx26
Papers on Kis
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
New
Supuran et al., Sesto Fiorentino, Italy. In Bioorg Med Chem Lett, Feb 2016
Less effective inhibitors were topiramate, zonisamide, celecoxib, saccharin and hydrochlorothiazide as well as simple benzenesulfonamides incorporating amino, halogeno, alkyl, aminoalkyl and other moieties in the ortho- or para-positions of the aromatic ring (Kis of 202-933nM).
Fluorescent sulfonamide carbonic anhydrase inhibitors incorporating 1,2,3-triazole moieties: Kinetic and X-ray crystallographic studies.
New
Supuran et al., Sesto Fiorentino, Italy. In Bioorg Med Chem, Feb 2016
The new derivatives showed poor hCA I inhibitory properties, but were effective inhibitors against the hCA II (KIs of 366-127nM), CA IX (KIs of 8.1-36.9nM),
Cloning, characterization and anion inhibition studies of a γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
New
Capasso et al., Napoli, Italy. In Bioorg Med Chem, Feb 2016
Perchlorate, tetrafluoroborate, fluoride and bromide were not inhibitory, whereas cyanate, thiocyanate, cyanide, hydrogensulfide, carbonate and bicarbonate showed KIs in the range of 1.4-4.4mM.
The human carbonic anhydrase isoenzymes I and II inhibitory effects of some hydroperoxides, alcohols, and acetates.
New
Supuran et al., Erzurum, Turkey. In J Enzyme Inhib Med Chem, Jan 2016
These compounds were good hCA I inhibitors (Kis in the range of 24.93-97.99
Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
New
Supuran et al., Sesto Fiorentino, Italy. In Bioorg Med Chem Lett, Jan 2016
The enzyme was inhibited in the submillimolar range by most inorganic anions (cyanate, thiocyanate, cyanide, bicarbonate, halides), whereas sulfamide, sulfamate, phenylboronic/phenylarsonic acids were micromolar inhibitors, with KIs in the range of 9-77μM.
Inhibition of mammalian carbonic anhydrase isoforms I-XIV with a series of phenolic acid esters.
New
Supuran et al., Sesto Fiorentino, Italy. In Bioorg Med Chem, Dec 2015
Many of the mammalian isozymes of human (h) or murine (m) origin, hCA I-hCA XII, mCA XIII and hCA XIV, were inhibited in the submicromolar range by these derivatives (with KIs of 0.31-1.03μM
Anion inhibition studies of the dandruff-producing fungus Malassezia globosa β-carbonic anhydrase MgCA.
New
Supuran et al., Sesto Fiorentino, Italy. In Bioorg Med Chem Lett, Dec 2015
Here we present an anion inhibition study of this enzyme, reporting that metal complexing anions such as cyanate, thiocyanate, cyanide, azide are weak MgCA inhibitors (KIs ranging between 6.81 and 45.2mM) whereas bicarbonate (KI of 0.59mM) and diethyldithiocarbamate (KI of 0.30mM) together with sulfamide, sulfamate, phenylboronic acid and phenylarsonic acid were the most effective inhibitors detected so far, with KIs ranging between 83 and 94μM.
Emerging kinase inhibitors of the treatment of gastric cancer.
Review
New
Tonini et al., Roma, Italy. In Expert Opin Emerg Drugs, Sep 2015
In this scenario, kinase inhibitors (KIs), smaller intracellular agents, could be an interesting and novel type of targeted treatment of metastatic GC both in first and further lines of therapy.
Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.
Review
New
Prince et al., Bethesda, United States. In Cell Stress Chaperones, Sep 2015
Despite the initial success of kinase inhibitors (KIs), the ability of cancer to evolve resistance and reprogram oncogenic signaling networks has reduced the efficacy of kinase targeting.
The evolving field of kinase inhibitors in thyroid cancer.
Review
Faggiano et al., Napoli, Italy. In Crit Rev Oncol Hematol, 2015
Thus, kinase inhibitors (KIs) are very relevant in this field.
Prestin-Dependence of Outer Hair Cell Survival and Partial Rescue of Outer Hair Cell Loss in PrestinV499G/Y501H Knockin Mice.
Zheng et al., Evanston, United States. In Plos One, 2014
499 KI mice were also backcrossed onto the FVB murine strain, which retains excellent high-frequency hearing well into adulthood, to reduce the compounding effect of age-related hearing loss associated with the original 499 prestin KIs.
Withdrawal of anticancer therapy in advanced disease: a systematic literature review.
Barclay et al., Cambridge, United Kingdom. In Bmc Cancer, 2014
Newer drugs include molecular targeted agents (MTAs), in particular, small molecule kinase-inhibitors (KIs), which are administered orally.
MARCKS Signaling Differentially Regulates Vascular Smooth Muscle and Endothelial Cell Proliferation through a KIS-, p27kip1- Dependent Mechanism.
Monahan et al., Baltimore, United States. In Plos One, 2014
MARCKS knockdown resulted in decreased phosphorylation of p27kip1 at threonine 187 and serine 10 as well as, kinase interacting with stathmin (KIS), cyclin D1, and Skp2 expression.
Synergizing immunotherapy with molecular-targeted anticancer treatment.
Review
Fernández, Buenos Aires, Argentina. In Drug Discov Today, 2014
The therapeutic opportunity for anticancer kinase inhibitors (KIs) that block cell-signaling pathways is materializing.
Update: the status of clinical trials with kinase inhibitors in thyroid cancer.
Review
Santoro et al., Napoli, Italy. In J Clin Endocrinol Metab, 2014
OBJECTIVE: This update reviews the molecular genetics of thyroid cancer and the clinical trials evaluating kinase inhibitors (KIs) in patients with locally advanced or metastatic disease.
Genetic and molecular exploration of UHMK1 in schizophrenic patients.
GeneRIF
Jamain et al., France. In Psychiatr Genet, 2011
The contribution of UHMK1 gene in schizophrenia susceptibility, was explored.
Crystallization and preliminary X-ray analysis of tubulin-folding cofactor A from Arabidopsis thaliana.
GeneRIF
Li et al., Beijing, China. In Acta Crystallogr Sect F Struct Biol Cryst Commun, 2010
crystal of tubulin-folding cofactor A diffracted to 1.6 A resolution using synchrotron radiation and belonged to space group I4(1), with unit-cell parameters a=55.0, b=55.0, c=67.4 A
Signaling from the secretory granule to the nucleus: Uhmk1 and PAM.
GeneRIF
Eipper et al., Farmington, United States. In Mol Endocrinol, 2010
Uhmk1 was concentrated in the nucleus, but cycled rapidly between nucleus and cytosol.
Expression of kinase interacting with stathmin (KIS, UHMK1) in human brain and lymphoblasts: Effects of schizophrenia and genotype.
GeneRIF
Eastwood et al., Oxford, United Kingdom. In Brain Res, 2010
KIS is expressed in neurons, and its encoded protein is localised to the nucleus and cytoplasm. No difference in KIS expression was found between schizophrenics and controls or in the lymphoblast cell lines.
KIS protects against adverse vascular remodeling by opposing stathmin-mediated VSMC migration in mice.
GeneRIF
Nabel et al., Bethesda, United States. In J Clin Invest, 2008
Phosphorylation of p27Kip1 by KIS leads to cell-cycle progression, whereas the target sequence and the physiological relevance of KIS-mediated stathmin phosphorylation in VSMCs
share on facebooktweetadd +1mail to friends